Group 1 - The company reported a revenue of 457 million RMB and a gross profit of 197 million RMB for the six months ending June 30, 2025, with R&D costs amounting to 46.046 million RMB [1] - The hematology testing services saw a steady growth in hospital partnerships, adding over 90 new hospital clients in the first half of 2025, with the pediatric hematology segment adding 48 new cooperative hospitals [1] - The NGS testing IG/TCR rearrangement technology product sales increased by over 50%, showcasing the company's core technological advantages and product features [1] Group 2 - The company emphasized innovation-driven development, with 33 research articles published and 67 patents applied for in the first half of 2025, of which 29 were granted [2] - A total of 56 new R&D testing projects were added during the reporting period, including 16 related to molecular biology testing technology and 16 related to flow cytometry testing technology [2] - The core product in the immune repertoire, used for minimal residual disease detection in hematological malignancies, expanded its coverage to over 160 institutions across 26 provinces, with revenue growth of nearly 30% compared to the same period in 2024 [2]

Core Insights - The company reported a revenue of 457 million RMB and a gross profit of 197 million RMB for the six months ending June 30, 2025, with R&D costs amounting to 46.046 million RMB [1] - The hematology testing services saw a steady growth in hospital partnerships, adding over 90 new hospital clients in the first half of 2025 [1] - The pediatric hematology segment continued to expand, with 48 new hospital collaborations established during the same period [1] - The NGS testing product for IG/TCR rearrangement technology experienced over 50% sales growth, highlighting the company's core technological advantages [1] - In the neurology sector, the company expanded its testing projects, adding 34 new tests and 44 new collaborating hospitals [1] Innovation and R&D - The company emphasized innovation-driven development, publishing 33 research articles and applying for 67 patents, with 29 granted and 24 copyrights obtained in the first half of 2025 [2] - A total of 56 new R&D testing projects were introduced, including 16 related to molecular biology, 16 to flow cytometry, 7 to cytogenetics, and 6 to pathology [2] - The core product in the immune repertoire, used for minimal residual disease detection in hematological malignancies, expanded to over 160 institutions across 26 provinces, with revenue growth of nearly 30% compared to the same period in 2024 [2] - The company's subsidiary, Kangsheng Beitai, achieved a perfect score in the EuroClonality EQA program, marking a significant step towards internationalization in the field of immune repertoire testing in China [2]